Jamie Innes,Andrew Whiting,Peter McCaffery
Jamie Innes
Introduction: All‑trans‑retinoic acid orchestrates vertebrate development and adult tissue homeostasis. Because both deficiency and excess are deleterious, atRA concentrations must be precisely controlled, making its lo...
Slobodan M Janković
Slobodan M Janković
Introduction: There are multiple interactions between drugs and the human microbiome that can influence drug effects and pharmacokinetics, but few clinical studies have examined the influence of sex on these interactions....
Pharmacogenomic and inflammatory determinants of antipsychotic-induced extrapyramidal toxicity in Egyptian patients with schizophrenia [0.03%]
埃及精神分裂症患者抗精神病药所致锥体外系毒性的药理基因组学和炎症决定因素
Asmaa Mohamed Sayed Ahmed,Asmaa Mohammad Moawad,Mennat-Allah Tarek et al.
Asmaa Mohamed Sayed Ahmed et al.
Background: Extrapyramidal symptoms (EPS) are side effects of antipsychotic therapy, and genetic and inflammatory mechanisms may contribute to EPS risk. This study investigated the associations among ABCC2 (rs4148396) gen...
Post-marketing pharmacovigilance of tedizolid: emerging safety signals [0.03%]
泰地唑胺上市后药物流行病学研究发现的安全性信号
Haiping Yao,Guoping Gan,Zhu Wang
Haiping Yao
Background: Tedizolid (TED), an oxazolidinone antibiotic, has improved pharmacokinetics compared with linezolid, but its real-world safety profile remains incompletely defined. Post-marketing surveillance helps detect adv...
Impact of green tea on pharmacokinetics in cardiovascular therapy: current insights [0.03%]
绿茶对心血管治疗药代动力学的影响：当前见解
Shingen Misaka,José Pablo Werba
Shingen Misaka
Substrate-specificity of pharmacogenomic variability - clinical relevance and emerging predictive strategies [0.03%]
药理基因组变异的底物特异性——临床相关性及预测策略的发展
Yitian Zhou,Yoomi Park,Volker M Lauschke
Yitian Zhou
Introduction: Genetic variation in drug-metabolizing enzymes and transporters contributes to interindividual differences in drug efficacy and toxicity. While current pharmacogenomic practice typically assigns fixed functi...
Microbiome-driven PKs: addressing research gaps and shaping future directions beyond the narrative review [0.03%]
肠道微生物群驱动的药物代谢动力学：超越叙述性综述的研究差距和未来方向
Andrej Belančić,Almir Fajkić,Yun Wah Lam et al.
Andrej Belančić et al.
Diagnosing idiosyncratic drug-induced liver injury: lessons from monocyte-derived hepatocyte-like cells [0.03%]
单核细胞衍生的肝细胞样细胞在药物性肝损伤诊断中的应用及启示
Maria Fernanda Vargas,Stuart Astbury,Jane I Grove et al.
Maria Fernanda Vargas et al.
Introduction: Idiosyncratic drug-induced liver injury (iDILI) is an unpredictable adverse drug event that often involves an abnormal immune response. iDILI is a challenge in the development of new drugs and the diagnosis ...
An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications [0.03%]
抗抑郁药物和抗惊厥药的药代动力学和药效学相互作用的新进展
Edoardo Spina,Maria Antonietta Barbieri,Marika Alborghetti et al.
Edoardo Spina et al.
Introduction: This is an update of a prior review of clinically relevant pharmacokinetic (PK) and pharmacodynamic (PD) drug-drug interactions (DDIs) between antidepressants and antiseizure medications (ASMs). ...
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025 [0.03%]
新疗法的ADME研究：2025年的挑战与机遇
Hongbin Yu,Richard Dambra,Gary Chan et al.
Hongbin Yu et al.
Introduction: Advancements in absorption, distribution, metabolism, and excretion (ADME) science and pharmacokinetics (PK) have reshaped the drug development landscape, markedly reducing clinical attrition due to unfavora...